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Autologous vessels for repairing damaged or malformed 
arteries or veins have found an increasingly widespread 
use. Often, these are employed in vascular surgery to 
make coronary bypasses, lower limb bypasses, arteriove-
nous shunts, or repair congenital defects of the pulmonary 
outflow tract. However, their use may be extended to vas-
cular injuries, mainly caused by penetrating trauma sec-
ondary to improvised explosive devices and high-velocity 
gunshot wounds, common in wartime and civilian trauma 
(1, 2). Polytrauma patients usually require a shorter opera-
tive time to facilitate resuscitation and normalization of hy-
pothermia, coagulopathy, and metabolic acidosis; a rapid 
successful repair of traumatic arterial lesions is crucial to 
stop ongoing hemorrhage as well as to facilitate distal 
blood flow to the extremities. Currently, among autologous 
native vessels, the saphenous vein is the most used for 
small-diameter arterial wall replacement (1-3). This “ready-
to-use” patch is highly tolerated by the immune system, 
but the availability of harvesting sites can be limited in 
patients with diffuse vascular disease or trauma. Further-
more, in critically injured patients, the physiologic insult in-
curred during the harvesting of the vein must be weighed 
against the use of an alternative patching agent.
To reduce operative times, a biologic conduit may offer a 
wonderful substitute for a vascular graft. Biologic patch 
materials currently in use are limited to prosthetic materials 
and autologous, allogenic or xenogenic (glutaraldehyde-
fixed) pericardium (4-10). Unfortunately, these patches 
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have well-known limitations, including infection, thrombo-
genicity, calcification, foreign body reaction, and lack of 
growth potential (4-10). Artificial vascular grafts manufac-
tured from synthetic materials, for example, polyester and 
expanded polytetrafluoroethylene (ePTFE), have also been 
routinely used to reconstitute the blood flow in patients 
with various cardiovascular disorders. Conventional grafts 
have clinically shown satisfactory durability; however, they 
still have several disadvantages, such as thrombogenicity, 
late stenosis and occlusion from intimal hyperplasia (es-
pecially in small caliber grafts), susceptibility to infection, 
pseudoaneurysm formation, and lack of growth potential 
(3, 11-13).
Vascular tissue engineering has emerged as one of the 
most promising approaches to producing mechanically 
competent vascular substitutes. Clinical demands for a 
ready-to-use, reabsorbable vascular patch cover different 
fields of surgery: heart surgery (treatment of ischemic heart 
diseases), vascular surgery (distal revascularization of 
lower limbs), neurosurgery (repair of intracranial arteries), 
pediatric vascular surgery, and rare cases of microsurgical 
reconstruction after severe hand traumas.
Vascular tissue engineering: the biological bases
Completely bioresorbable vascular conduits capable of in-
ducing regeneration and growth of a new vascular wall may 
overcome the limitations of contemporary artificial patches 
that are nonviable, artificial, or allogenic materials lacking 
the capacity of growth, repair, and remodeling. These in-
trinsic properties currently limit the long-term function of 
the artificial patch, creating a substantial burden of patch 
failure and related reoperations. The need for a prosthetic 
patch that performs as a vascular regeneration guide has 
led investigators to pursue many avenues in tissue engi-
neering, starting from two axioms: (1) the native vascular 
function, particularly the mechanical function, depends on 
structure as much as it depends on composition, and (2) 
the tissue-engineered vessel should serve as a functional 
remodeling template, providing function during the remod-
eling, and, at the same time, a template for the alignment 
of the remodeled tissue. Therefore, from implantation to 
complete absorption, an ideal vascular scaffold should 
reproduce the typical mechanical and biological features 
of a natural vessel: it should have anti-inflammatory and 
anti-thrombotic properties, and minimize intimal hyperpla-
sia; it should be compliant but, at the same time, resistant 
to shear stress and blood pressure; it should avoid blood 
leakage or hemorrhage; and finally, it should be suturable, 
allowing the needle to pass, without lesions or lacerations. 
Apart from specific physical properties, tissue engineer-
ing strategies rely on the ability of cells (transplanted or 
host) to adhere to and migrate within the construct, and to 
remodel its composition and/or structure. Of course, the 
scaffold must be replaced by a functional cell-derived ex-
tracellular matrix (ECM) on the same time scale.
Remodeling also determines the ultimate mechanical and 
biological properties. Scientists in the field of tissue en-
gineering are now applying the principles of cell biology, 
material science, and biomedical engineering to create bi-
ological substitutes that will restore and maintain normal 
function in diseased and injured tissues/organs (14-16). 
It has been demonstrated that tissue morphogenesis is 
heavily influenced by interactions between cells and ECM 
during normal tissue development. While simple polymer-
ic scaffolds that have been used in the past provide ar-
chitectural support for a neo-tissue development, they do 
not adequately mimic the complex interactions between 
tissue-specific cells and tissue-specific ECM that promote 
a functional tissue regeneration. Thus, future advances 
in tissue engineering will depend on the development 
of novel scaffolding systems that actively modulate cell 
behaviors to build healthy, vital tissue.
MATERIALS AND METHODS IN VASCULAR 
TISSUE ENGINEERING
Decellularized tissue matrices
Due to a dearth of methods for de novo construction of a 
complex structure capable of imitating natural ECM, decel-
lularized tissue matrices are currently considered an ideal 
scaffolding system due to their structural and mechani-
cal similarity to native tissues and because they contain 
tissue-specific ECM proteins that remain after decellular-
ization. Interestingly, Yoo and colleagues reviewed decel-
lularization techniques and possible methods for using 
these decellularized matrices for whole organ engineering 
(17). Decellularized matrices have already been used for 
many tissue engineer applications. Kim et al developed 
a composite scaffold that was composed of a collagen 
matrix derived from decellularized porcine bladder sub-
mucosal matrix and synthetic poly(lactide-co-glycolide) 
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(PLGA) polymer (18). This composite scaffold provides a 
microenvironment that facilitates osteogenic differentia-
tion of amniotic fluid-derived stem cells. Furthermore, Choi 
et al investigated the interactions between the ECM envi-
ronment and human corneal endothelial cells to improve 
cell proliferation and function (19). Following this marked 
path, vascular tissue engineering has experimented with 
new decellularized constructs. Thanks to studies like those 
just mentioned, which have investigated the interactions 
between the ECM environment and mesenchyme-derived 
cells, it has been possible to develop tubular decellular-
ized matrices supporting the growth of a neointima with 
endothelial and smooth muscle cells (20). Decellular-
ized arteries, from allogenic and xenogenic sources, are 
attractive scaffolds for tissue-engineered vascular grafts 
(TEVGs) thanks to their mechanical and biological proper-
ties (20). However, these natural scaffolds are limited by 
the lack of precise manufacturing control of the physical 
and mechanical properties as well as by problems with in-
flammation and calcification (21). The search for a viable 
off-the-shelf, small- diameter vascular graft that can match 
autograft performance in terms of mechanical properties, 
cell compatibility, and vascular healing has been the focus 
of many research efforts, but, to date, has remained an 
elusive target.
Electrospinning
Another approach in the development of biomimetic 
structures has been suggested by the textile industry. 
To date, electrospinning is a chemical engineering tech-
nique widely used as a fabrication method to generate 
nanofibers with diameters ranging from 100 nm or less 
to several micrometers, for various textile applications. 
Although many other scaffold fabrication technologies 
are routinely used in tissue engineering, only a few pro-
vide constructs with critical similarities to natural ECM 
like those that electrospinning can provide. Electros-
pinning has become a popular alternative fabrication 
method during the last two decades, as it can be applied 
to many disciplines and it is relatively simple and inex-
pensive. Shin and colleagues reviewed the current ap-
proaches to the development of electrospun nanofibers 
as a scaffold for tissue engineering applications (22). 
These electrospun scaffolds can also be functionalized 
by adding biochemical and mechanical cues to enhance 
cellular interactions for tissue engineering applications. 
Levorson et al described their work with fabrication and 
characterization of multi-scale electrospun scaffolds for 
cartilage regeneration (23). These scaffolds were able 
to maintain scaffold cellularity in serum-free conditions 
as well as aid the deposition of glycosaminoglycans. Xu 
et al presented a novel, controllable, dual protein delivery 
system through electrospun fibrous scaffolds with differ-
ent hydrophilicities (24). Starting from these ideas, Zhang 
et al built up a double-layered electrospun membrane 
composed of chitosan hydrogel/poly(ethylene glycol)- 
b-poly(l-lactide-co-caprolactone) (PELCL) electrospun 
membrane loaded with VEGF (inner layer) and emulsion/
PELCL loaded with PDGF (outer layer) to regulate prolif-
eration of vascular endothelial cells and vascular smooth 
muscle cells (25). Only a rapid endothelialization along 
the lumen of grafts followed by proliferation of vascu-
lar smooth muscle cells around the exterior can prevent 
thrombosis and guarantee the right vascular compliance. 
Further applications of electrospinning technique are de-
scribed in the following paragraphs.
Cell-seeded scaffolds
To improve biocompatibility features and promote remodel-
ing and reabsorption, materials are usually seeded with hu-
man mesenchyme-derived cells. The first clinical application 
of a tissue-engineered vascular patch with pretreatment of 
human bone marrow cells, was reported by Shin’oka (26). 
Likewise, tissue-engineered biodegradable materials with 
autologous cell seeding before patch repair, where a biore-
actor culture system was used, have been well documented 
as potential cardiovascular patches (27-33). Oh and Lee 
reviewed hydrophilization of synthetic biodegradable poly-
meric scaffolds for improving cell/tissue compatibility (34). 
This technique has been considered a simple and effective 
approach to achieve desirable in vitro cell culture and in vivo 
tissue regeneration within the synthetic polymeric scaffolds. 
In a very recent, cutting-edge study, polycaprolactone (PCL) 
/polylactide (PLA) and PCL/PLA/polyethylenglycol (PEG) 
electrospun small caliber vascular grafts and ePTFE grafts 
of the same size have been pre-coated with blood, gelatine 
or fibronectin and seeded with endothelial cells from human 
term placenta. The best results have been obtained with fi-
bronectin-coated PCL/PLA/PEG grafts. Here, the number of 
attached viable cells was 78% to 81% higher than fibronec-
tin pre-treated ePTFE grafts. Cells attached to PCL/PLA/PEG 
grafts appeared in physiological cobblestone morphology. 
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Viability analysis showed a high cell viability of more than 
98% (35).
The feasibility of creating a completely biodegradable vas-
cular regenerating guide directly in vivo, without chemical 
and cellular preconditioning in vitro, is of great interest. 
This approach may overcome the main problems related 
to present techniques. Tissue-engineered grafts currently 
being investigated require an extended period of prepara-
tion, and thus they cannot be used in emergency situations 
(36-38). Furthermore, the prolonged duration of culture in-
creases the risk of infection and raises costs in terms of 
personnel, equipment, and materials needed. In TEVGs 
autologous cell seeding and culture or growth with biore-
actors before the operation is usually necessary to improve 
their antithrombogenicity and performance. Many strate-
gies have been attempted to facilitate regeneration of au-
tologous tissue on tissue-engineered materials. A major 
method is preoperative cellular manipulation (26, 39, 40). 
Kaushal and coworkers (39) demonstrated functional small 
diameter neovessels produced with endothelial progenitor 
cells. Another effective method is the use of a bioreactor 
(39, 41, 42). Campbell and associates (43) suggested that 
the host’s own peritoneal cavity is an effective bioreactor 
and showed that it is feasible to grow vascular prosthe-
ses within it. Also, Hoerstrup and colleagues (42) demon-
strated the growth capacity of cell-seeded TEVGs grown 
in vitro for 21 days under biomimetic conditions.
Although the utility of these pretreatments is fully recog-
nized, their short comings, including invasiveness, risk of 
contamination, and the need for preparation time, have led 
to hesitation in their clinical use. For these reasons, Torikai 
et colleagues (44) used in situ cellularization as an alterna-
tive method, more suitable for clinical application because 
of its ready availability (33, 45). The patch they designed 
was composed of three layers: the interior (luminal side) 
was composed of knitted PGA compounded with collagen 
microsponge, the middle layer was PCL, and the exterior 
was composed of woven PLA. This PGA/PLA graft showed 
evidence of good in situ cellularization, including relatively 
early endothelialization and population with functioning 
SMCs, after implantation into porcine aorta. The graft was 
durable enough to withstand high-pressure conditions for 
at least 12 postoperative months, despite the presence of a 
residual PLA layer, and also demonstrated the potential to 
acquire intrinsic physiologic vascular function. Considering 
the established use of artificial grafts for aortic surgery and 
the need for small-diameter prostheses, the complete and 
early endothelialization demonstrated by their TEVG was 
meaningful, particularly in the setting of small diameter 
vascular structures, such as peripheral arteries. The limita-
tions of study were the lack of regenerated elastin and the 
residual PLA layers.
Notwithstanding these encouraging results, the ex vivo 
cell-seeding procedure is complicated, invasive, expen-
sive, and can cause contaminations. To overcome these 
problems, the last few years have marked a substantial 
paradigm shift in design criteria for modern synthetic bio-
materials, and materials equipped with molecular cues 
mimicking certain aspects of the structure or function of 
natural extracellular microenvironments have quickly been 
developed (46-50).
Synthetic biodegradable polymeric scaffolds
Takahashi et al developed a novel tissue-engineered patch 
made of PGA/PLA that showed constructive in situ remod-
eling by site-specific host cells without prior ex vivo cell 
seeding (51). Unfortunately, PGA can induce a local inflam-
matory response following patch repair (52). More recently, 
Giammona et al have reported the in vivo application on 
a murine animal model of two electrospun biodegradable 
materials, specifically designed to create tubular structures. 
In one case a α, β-Poly [(N-hydroxyethyl)-dl-aspartamide] 
(PHEA)-PLA mixture was co-spun with silk fibroin (Fibro-
PHEA-PLA) by a parallel electrospinning process to obtain 
a scaffold with two different polymeric fibers. In the other 
case, PHEA-PLA was mixed with PCL (PCL-PHEA-PLA) to 
obtain a hybrid fibers scaffold. The in vitro assay showed 
fibroblast colonization in both materials. Histopathological 
findings showed that after implantation a neutrophilic reac-
tion associated to colliquative necrosis was predominant, 
particularly for PCL-PHEA-PLA. Fibro-PCL-PHEA caused 
a non-organized stromal reaction (53). Pitarresi et al have 
improved PHEA-PLA by producing a new copolymer named 
a,b-poly(N-2-hydroxyethyl) (2-aminoethylcarbamate)-D, L- 
aspartamide-graft-polylactic acid (PHEA-EDA-g-PLA) as a 
starting material for producing a fibrillar scaffold for vascu-
lar regeneration (54). Thanks to the presence of free amino 
and hydroxyl groups in PHEA-EDA-g-PLA, the electrospun 
scaffold has been bound to heparin, a known natural an-
ticoagulant molecule (55). Through electrostatic interac-
tion, heparin is also able to retain growth factors like basic 
fibroblast growth factor (bFGF) (56-58). For this reason, 
the presence of heparin in avascular grafts could prevent 
© 2014 Wichtig Publishing - ISSN 0391-3988 5
Palumbo et al
thrombosis phenomena and improve cell attachment and 
proliferation. In this case, the scaffolds obtained have 
been able to allow the formation of new endothelial tissue, 
making them of potential use for the production of bioengi-
neered blood vessels (54). Due to their inflammatory poten-
tial many researchers have abandoned synthetic polymers 
and have tested vascular patches entirely made of a benzyl 
ester of hyaluronic acid (HA).
Hyaluronic acid scaffolds
HA can be processed to obtain several types of devices 
such as tubes, membranes, nonwoven fabrics, gauzes, 
and sponges. All these scaffolds are highly biocompatible. 
In the human body they do not elicit any adverse reac-
tions and are reabsorbed by the host tissues (59). HA is the 
only nonsulphated glycosaminoglycan of ECM. Despite its 
simple structure, HA is involved in a great number of bio-
logical functions, such as cell proliferation and migration, 
morphogenesis, wound healing, inflammation, angiogen-
esis, and tumor growth (60-64). An important biological 
role is related to HA oligosaccharides that stimulate cy-
tokine secretion and endothelial cell proliferation (60-64). 
Moreover, recent studies indicate that HA may inherently 
stimulate endothelialization, favoring the recruitment of 
endothelial cells and endothelial progenitor cells (EPCs) 
(43, 45). EPCs can migrate and adhere inside HA-based 
biomaterials, maintain their preendothelial phenotype, and 
express angiogenic factors, especially within the first week 
of growth (63, 65). These results indicate that HA-based 
biomaterials could be promising candidates as a vehicle 
for EPCs for regenerative medicine applications. They may 
also overcome problems related to current vascular im-
plant materials that insufficiently recruit endothelial cells to 
form a normally functional and confluent endothelium, a 
key challenge to reinstating vascular homeostasis at the 
surgical site.
An Italian team obtained stimulating results in testing vascu-
lar prostheses entirely made of HA in rat and pig experimen-
tal models (65-68). In this case, human vascular cells, such 
as endothelial cells (62) and smooth muscle cells (SMCs) 
(63), were grown in vitro on benzylic esters of hyaluronic 
acid (namely HYAFF-11 biomaterials) constructs to develop 
new tissue-engineered vascular substitutes. Previous in vivo 
studies (65-68) confirmed that HYAFF tubes could sequen-
tially orchestrate the vascular regeneration events needed 
for very small artery reconstruction. HYAFF-11 was shown 
to be very well tolerated and to elicit no adverse reactions 
in clinical practice (62, 63, 69). More recently, Du et al have 
fabricated well-aligned nanofibrous scaffolds with PCL us-
ing a high-speed rotating collector. They then modified those 
surfaces with HA and studied the synergistic effect of the 
scaffolds on the in vitro behavior of the endothelial cells. The 
results of adhesion and the morphology of human umbilical 
vein endothelial cells (HUVECs) showed that the HA-coating 
aligned PCL (HA-aPCL) nanofibrous scaffolds could highly 
promote attachment and guide the HUVECs bipolar spread 
with the parallel, aligned nanofibers. Furthermore, HUVECs 
on the HA-aPCL formed a confluent monoendothelial cell 
layer and exhibited superior protein expression levels of von 
Willebrand factor. This study suggested that the combina-
tion of aligned nanostructure and HA modification was more 
capable of promoting the regeneration of functional endo-
thelium for vascular tissue engineering than the use of either 
individually (70).
HA is also often mixed with other ECM polymers to better 
reproduce the complexity and biological role of the natural 
ECM. In some studies, HA has been combined with colla-
gen fibers, showing advantages such as the enhancement 
of cell migration and division compared to either material 
on its own (71, 72). Another potential material applicable to 
TEVG field is HA-EDA-g-α-elastin copolymer. In this case 
HA was functionalized with EDA and the resulting deriva-
tive was reacted with α-elastin, a water-soluble protein 
that maintains the main biological performance of native 
elastin. The presence of unreacted amino groups in HA-
EDA-g-α-elastin allow chemical crosslinking with ethylene 
glycol diglycidyl ether (EGDGE) and the production of po-
rous scaffolds. The authors evaluated attachment, viability, 
and proliferation of primary rat dermal fibroblasts and um-
bilical artery smooth muscle cells, obtaining good results. 
Furthermore, the prepared scaffold showed good water af-
finity, a resistance in simulated physiological fluid, and an 
appropriate susceptibility to hydrolysis by hyaluronidase. 
Undoubtedly, thanks to the presence of HA and α-elastin, 
a potential application of the investigated scaffolds could 
be dermal or vascular regeneration, since both compo-
nents are abundant in these tissues where they play im-
portant biological functions (73).
Elastin into scaffolds: the keystone of TEVGs
A major structural element of arterial walls is elastic 
fiber, which endows vessels with the critical property of 
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elastic recoil (74). In arteries, elastin dictates tissue me-
chanics at low strains before stiffer collagen fibers are 
engaged. It confers elasticity, preventing dynamic tissue 
creep by stretching under load and recoiling to its origi-
nal configuration after the load is released. In addition to 
mechanical responsiveness, elastin is a potent autocrine 
regulator to vascular SMC activity, and this regulation is 
important for preventing fibrocellular pathology. Finally, 
elastin degradation associated with matrix metalloprotein-
ase (MMP) activity is a cell-mediated process, observed 
in almost all types of vascular calcification. Elastin pep-
tides associated with transforming growth factor-β could 
induce osteogenic gene expression in SMCs, possibly via 
elastin laminin receptor (ELR) signaling (13, 74). Their pres-
ence in a vascular graft would greatly enhance design and 
patency; furthermore, elastic fibers also influence vascular 
cell behavior through direct interaction and by regulation 
of growth factor activation. Elastin knockout studies and 
clinical observations have revealed the essential regulatory 
function of elastin during artery development. In the ab-
sence of extracellular elastin accumulation, smooth mus-
cle proliferation leads to arterial stenosis (75-79). Thus, to 
ensure appropriate mechanical function and prevent seri-
ous complications, successful artery replacements must 
incorporate an elastic component.
Approaches to date have included building tissue replace-
ments on an elastin scaffold isolated from cadaveric tis-
sues, supplying soluble tropoelastin to a cell culture, or 
designing biocompatible synthetic elastic polymers (13). 
One of the most promising approaches was described by 
L’Heureuxet al (80-82), who developed a completely au-
tologous technique called sheet-based tissue engineering. 
Dermal fibroblasts are obtained from a small skin biopsy 
and grown in conditions that promote an engineered com-
plete vessel, ready to be implanted in six months. This ap-
proach is time consuming, with total production time at 
~24 weeks. It is conceivable that in previous techniques 
(26, 83-86), the change from two-dimensional to three-
dimensional culture conditions utilizing porous scaffolds 
may have contributed to a loss in elastin biosynthesis by 
SMCs. It is now known that the scaffold must provide the 
appropriate chemistry for SMCs to secrete elastin. Few 
scaffolds are able to promote elastin biosynthesis.
One of the most promising ECM-derived polymers is hyal-
uronan, as discussed earlier. In vitro studies with gel prepa-
rations of hyaluronan (87, 88) have confirmed elastogenesis 
in neonatal SMCs. In 2012, McKenna et al (89) electrospun 
small-diameter vascular grafts containing recombinant hu-
man tropoelastin (rTE), the monomer unit of elastin, that, 
when cross-linked, mimics native elastin fibers. The ma-
terial provided both the compliance and support of endo-
thelial cell adhesion for a component of a vascular graft 
biomaterial, but it lacked the tensile strength to support 
in vivo arterial pressures. The authors concluded that, for 
vascular graft applications, the tensile strengths of the prTE 
scaffolds should be further increased by reinforcement or 
co-spinning with either collagen or synthetic materials. In-
terestingly, Bashur et al (90) have reviewed many important 
issues related to elastin-based TEVGs. Starting from a de-
scription of the current challenges that exist in the field of 
elastic matrix engineering, specifically for vascular applica-
tions, they continue by introducing the specific targets and 
processes that impact elastogenesis, and conclude with a 
review of current progress toward achieving robust elasto-
genesis in TEVGs aimed at clinical use.
Three-dimensional (3D) printed vessels
Several rapid prototyping techniques and materials, from 
designs as simple as a single channel (91), to designs that 
recreate the complex geometries of vascular pathways (92), 
and even scaffolds based on complex collagen forms (93), 
have been used to achieve a vasculature reconstruction that 
is as natural as possible. Currently, solid freeform fabrication 
(SFF) as well as inverted colloidal crystal (ICC) fabrication or 
the newly emerging multi-photon absorption polymerization 
(MAP), provide precise controllability over 3D matrix archi-
tecture at a micro-scale level. Limited material selection and 
lack of submicro-scale structural resolution are the major 
shortcomings of these techniques. Bioprinting (94), in which 
cells and matrix are deposited dropwise, has been devel-
oped over the past decade but also is a slow, serial process 
with limitations on print resolution, materials, and cells.
In contrast to these methods, 3D sacrificial molding pro-
vides an intriguing alternative (95-97). Proof-of-concept 
studies have shown that a network of channels can be fab-
ricated by creating a rigid 3D lattice of filaments, casting 
the lattice into a rubber or plastic material, and then sacri-
ficing the lattice to reveal a microfluidic architecture in the 
bulk material. However, 3D sacrificial molding of perfusable 
channels has so far required the use of cytotoxic organic 
solvents or processing conditions for either removing the 
sacrificial filaments or casting the surrounding material, and 
thus could not be accomplished with aqueous-based ECMs 
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or in the presence of living cells. In their work, Miller et al 
(98) describe a biocompatible sacrificial material – a simple 
glass made from mixtures of inexpensive and readily avail-
able carbohydrates – and a means to 3D print the material 
to facilitate the rapid casting of patterned vascular networks 
in engineered tissues. In this case, they used the material as 
a cytocompatible sacrificial template in engineered tissues 
containing primary rat hepatocytes to generate cylindrical 
networks that could be lined with endothelial cells and per-
fused with blood under high-pressure pulsatile flow. Unfor-
tunately, it was difficult to achieve the cellular densities of 
native tissues (approximately 10-500 million cells per mL), 
but it demonstrated an avenue for building and studying 
such tissue mimics, in which the vasculature appears not to 
constrain the design space for the tissue itself, allowing for 
arbitrary cell types, matrices, and their patterning.
CONCLUSIONS
The way to create a perfectly absorbable structure capa-
ble of guiding the regeneration of a native human vessel 
is neither easy nor close to being achieved, but it is not 
too far off. Materials and methods used by the scientific 
community are amazingly complex and many efforts have 
been made to reach the perfection of animal structures, 
like ECM. Actually, ECM is an admirable intricate network 
of filamentous proteins connected by countless joints, 
immersed in a hydrogel rich in nutrients and growth fac-
tors, where the cellular component can perform its action 
of continuous control and remodeling. It is a very difficult 
challenge to try to reproduce and imitate the complexity 
of the ECM, but, probably, as often happens in scientific 
discoveries, the solution to the problem may be discov-
ered through some chance, simple intuitions. Certainly, the 
application of bioengineered materials in humans to repair 
damaged vascular structures will revolutionize current sur-
gical approaches to vascular pathology and will anticipate 
the transplantation of the whole organ into human being, 
giving an important boost to research in the field of regen-
erative medicine.
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